header logo en

 

10 facts web


Safety and Efficacy Study of

Pazopanib and Pembrolizumab

(MK 3475) in Advanced

Renal Cell Carcinoma (RCC)

 
 
 Last updated: January 27, 2017
 STATUS: Recruiting (accepting new patients) (per ClinicalTrials.gov/NCT02014636)

WHO

is the trial for?

Patients with kidney cancer (Renal cell carcinoma, RCC) who currently meet the following criteria:

WHAT

is the key question that this trial is attempting to answer?

This phase I/II study is a trial in two stages:

  • In the first stage it will determine the optimal dose of a tyrosine-kinase inhibitor in combination with an immune-oncological agent.
  • The second stage is evaluating the efficacy and safety of the drug combination administered in stage 1 as compared to the single-agents.

WHY

patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will further support the research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN

will the trial be open?

The study is open (currently recruiting) – 248 patients are currently expected to participate

WHERE

is the trial available?

The trial will be available in 5 cancer centres in the USA and UK.
For a complete list of trial locations, please click here:
 pdf Trial Locations pembrolizumab+pazopanib (344 KB)
 

STUDY

DESIGN

What does the study look like?

In phase I there will only be one study arm (group) for RCC patients: they will all be assigned pazopanib (Votrient TM) in combination with pembrolizumab (Keytruda™, MK-3475).

Participants will receive pazopanib orally and pembrolizumab intravenously in different dosages.

In phase II all participating patients will be randomly divided (by a computer) in three groups (arms). Please note that patients in all groups will receive an active medication. No patient receives a placebo.

Arm 1: Pazopanib monotherapy, administered orally
Arm 2: Pazopanib+pembrolizumab, pazopanib given orally + pembrolizumab intravenously
Arm 3: Pembrolizumab monotherapy given intravenously

HOW

do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

CONNECT

with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.

SHARE

your experience 

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS

of the study

The trial is still ongoing, but preliminary results were presented during ECC 2015 in September 2015: For preliminary results please read here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.
 
Back to clinical trials overview: How can I find an IO clinical trial for my cancer?